Chronic Plaque PsoriasisVALUENCT03982394
Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
An observational study of Chronic Plaque Psoriasis, run by AbbVie at 302 sites in 21 countries.
Trial summary
This study will assess the use of risankizumab in adult patients with moderate to severe chronic plaque psoriasis and compare risankizumab to other commonly used biologics. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Plaque Psoriasis
- How many people
- 2,759 participants
- Where
- 302 sitesin 21 countries
- Study dates
- 1 Jul 2019to 2 Sep 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This study will enroll adult subjects with moderate to severe plaque psoriasis.
Who may be able to join
- Confirmed diagnosis of moderate to severe chronic plaque-type psoriasis diagnosed by a specialist and presence of moderate to severe psoriasis symptoms according to physician's judgement at time of recruitment.
- Participant starting any approved treatment for psoriasis and physician's decision must be reached prior to recruitment in the study.
- Participant willing to continue with study documentation after cessation of therapy.
Who cannot join
- Unwillingness or inability to comply with study requirements.
- Participation in an interventional clinical trial, concurrently or within the last 30 days. Participation in a post-market observational study (PMOS) or Registry is acceptable.
Trial locations and contacts
302 sites in 21 countries.
302 sites in 21 countries
Germany76 sites
Bell, Andernach, DE /ID# 214545
Andernach, Rhineland-Palatinate, 56626
Praxis Dr. Mihaescu /ID# 213483
Augsburg, 86150
Mauer, Bad Kreuznach, DE /ID# 224876
Bad Kreuznach, 55543
Hautmedizin Bad Soden /ID# 213956
Bad Soden am Taunus, 65812
Timmel/Timm/Vorwerk, Bergen /ID# 214552
Bergen, 18528
Hasert & Hasert, Berlin, DE /ID# 213641
Berlin, 10117
Hautzentrum Friedrichshain /ID# 213981
Berlin, 10247
Weihe/Stavermann, Berlin, DE /ID# 214550
Berlin, 12353
Praxis Dr. med. Alexander Zich /ID# 245751
Berlin, 12681
Hautarztzentrum Tegel /ID# 214849
Berlin, 13507
Klinikum Rosenhoehe /ID# 215520
Bielefeld, North Rhine-Westphalia, 33647
Praxis fuer Innere Medizin/Rheumatologie /ID# 213653
Blaubeuren Abbey, 89143
Praxis T. Schadeck /ID# 213957
Bogen, 94327
Barth, Borna, DE /ID# 213643
Borna, 04552
Studienzentrum an der Hase GbR Dr. Weyergraf/Dr. Frick/Thomas Heiber /ID# 214466
Bramsche, Lower Saxony, 49565
Schwichtenberg, Bremen, DE /ID# 213650
Bremen, 28779
Elbe Klinikum Buxtehude /ID# 213366
Buxtehude, 21614
Praxis Herbst /ID# 222024
Darmstadt, 64283
Praxis Dr. Sbornik /ID# 213668
Deggendorf, 94469
Heidlas, Dessau-Rosslau, DE /ID# 217691
Dessau, 06842
Richter-Huhn, Dresden, DE /ID# 213659
Dresden, 01219
Praxis Dr. Korge /ID# 213475
Düren, 52349
Universitaetsklinikum Erlangen /ID# 213669
Erlangen, Bavaria, 91054
Dres. Cesko u. Körber /ID# 214850
Essen, 45130
Kurzen, Freising, DE /ID# 214567
Freising, Bavaria, 85354
Gemeinschaftspraxis Rietkoetter und Jablonka /ID# 213482
Gelsenkirchen, 45899
Praxis Dr. Lange /ID# 213984
Gera, 07548
Loth, Gernsbach, DE /ID# 214848
Gernsbach, 76593
Gross/Braeu, Giessen, DE /ID# 213367
Giessen, Hesse, 35390
Hautarztpraxis Dr. Viehmann /ID# 213675
Giessen, 35390
Brinkmann & Partner, Gladbeck, /ID# 214247
Gladbeck, 45964
Universitaetsklinikum Hamburg-Eppendorf /ID# 222464
Hamburg, 20246
Dermatologikum Hamburg /ID# 213978
Hamburg, 20354
Goldbek Medical /ID# 214570
Hamburg, 22303
Praxis Dres. Kaspari /Schenck /ID# 213649
Hanover, Lower Saxony, 30159
Hautarztpraxis Haßberge /ID# 213644
Haßfurt, 97437
Gemeinschaftspraxis Dres. Anika Hünermund/Mario Pawlak /ID# 213113
Heilbad Heiligenstadt, 37308
Reinecke, Holzminden, DE /ID# 215081
Holzminden, 37603
Universitaetsklinikum Jena /ID# 214259
Jena, Thuringia, 07747
Derma Sana /ID# 214544
Karlsruhe, 76133
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 213670
Kiel, Schleswig-Holstein, 24105
DermaKiel Allergie und Haut Centrum /ID# 213977
Kiel, Schleswig-Holstein, 24148
Grossmann, Koblenz, DE /ID# 214245
Koblenz, Rhineland-Palatinate, 56068
Praxis Dres. Bornemann/Reinerth /ID# 213368
Krefeld, 47798
Dres. Jacobs & Kollegen /ID# 213652
Kulmbach, 95326
Hautarztpraxis Langenau /ID# 213651
Langenau, Baden-Wurttemberg, 89129
Neubauer, Leipzig, DE /ID# 214548
Leipzig, Saxony, 04209
Noack-Wiemers, Leipzig, DE /ID# 213654
Leipzig, Saxony, 04289
Hagemeier, Loehne, DE /ID# 214845
Löhne, 32584
Dlugosz-Wolf, Luedenscheid, DE /ID# 222000
Lüdenscheid, 58507
Bruecher, Magdeburg, DE /ID# 213476
Magdeburg, Saxony-Anhalt, 39104
Praxis Dr. Raschke /ID# 225213
Magdeburg, Saxony-Anhalt, 39104
Universitaetsklinikum Magdeburg /ID# 215080
Magdeburg, 39120
Universitaetsmedizin Mainz /ID# 222025
Mainz, Rhineland-Palatinate, 55131
Dermatologie Quist-BAG Dres. med. Quist PartG /ID# 214249
Mainz, 55128
Universitatsklinikum Mannheim /ID# 214569
Mannheim, Baden-Wurttemberg, 68167
Beldio Research GmbH /ID# 213958
Memmingen, Bavaria, 87700
HMS GmbH Zimmer /ID# 225219
Merzig, Saarland, 66663
ZENTderma /ID# 213959
Mönchengladbach, 41061
Zentrum fur Hautgesundheit /ID# 222001
Neuwied, Rhineland-Palatinate, 56564
Duplicate_Praxis Dres. Kloss/Peterburgskiy /ID# 213960
Neuwied, 56564
Voelkel, Nuremberg, DE /ID# 213671
Nuremberg, Bavaria, 90419
Praxis Dr. Konstantin Ertner /ID# 213640
Nuremberg, 90402
Breitsprecher, Osnabrueck, DE /ID# 213672
Osnabrück, Lower Saxony, 49074
Kramer/Mortazawi, Remscheid /ID# 213477
Remscheid, North Rhine-Westphalia, 42897
Praxis Dr. Fränken /ID# 214546
Schwelm, 58332
Praxis Dr. Langhoff /ID# 214253
Schwerin, 19053
CMS3 Company for Medical Study /ID# 213676
Selters, Rhineland-Palatinate, 56242
Karl, Soest, DE /ID# 214547
Soest, North Rhine-Westphalia, 59494
Praxis Dres. Ziegler & Partner /ID# 213647
Stuttgart, 70190
Braun, Ueberlingen, DE /ID# 213646
Überlingen, 88662
Barnikol, Waltershausen, DE /ID# 213219
Waltershausen, 99880
Pfennig, Werdau, DE /ID# 213657
Werdau, 08412
Moeller, Wiesbaden, DE /ID# 213955
Wiesbaden, 65185
Hautarztpraxis Dr. med. Matthias Hoffmann /ID# 213444
Witten, 58453
Franz, Wolfenbuettel, DE /ID# 215355
Wolfenbüttel, 38300
Canada27 sites
CCA Medical Research /ID# 214446
Ajax, Ontario, L1S 7K8
SimcoDerm Medical and Surgical Dermatology Center /ID# 213081
Barrie, Ontario, L4M 7G1
SKIN Clinics /ID# 213082
Brandon, Manitoba, R7A 0L5
Beacon Dermatology Inc /ID# 213524
Calgary, Alberta, T3A 2N1
Duplicate_Stratica Medical /ID# 213526
Edmonton, Alberta, T5K 1X3
Alberta DermaSurgery Centre /ID# 230114
Edmonton, Alberta, T6G 1C3
Dr. Irina Turchin PC Inc. /ID# 212128
Fredericton, New Brunswick, E3B 1G9
LEADER Research /ID# 249701
Hamilton, Ontario, L8L 3C3
Lima's Excellence in Allergy and Dermatology Research Inc /ID# 231973
Hamilton, Ontario, L8L 3C3
Hamilton Health Sciences Corporation /ID# 214053
Hamilton, Ontario, L8L 8E7
Dermatrials Research /ID# 213523
Hamilton, Ontario, L8N 1Y2
Clinique D /ID# 212126
Laval, Quebec, H7N 6L2
Lynderm Research Inc /ID# 212124
Markham, Ontario, L3P 1X2
Al-Mohammedi Medicine Professional Corporation /ID# 215408
Mississauga, Ontario, L4W 0C2
DermEdge - Queensway East /ID# 213525
Mississauga, Ontario, L4Y 4C5
Angela Montgomery Medicine Professional Corporation /ID# 213615
Ottawa, Ontario, K1H 7X3
Dr Melinda Gooderham Medicine Professional Corporation /ID# 212133
Peterborough, Ontario, K9J 5K2
Centre de Recherche St-Louis /ID# 216325
Québec, Quebec, G1W 4R4
Karma Clinical Trials /ID# 213522
St. John's, Newfoundland and Labrador, A1A 4Y3
NewLab Clinical Research Inc. /ID# 213521
St. John's, Newfoundland and Labrador, A1C 2H5
Dr. Brown-Maher PMC INC. /ID# 212136
St. John's, Newfoundland and Labrador, A1E 1V4
Farheen Mussani Medicine Professional Corporation /ID# 213811
Stoney Creek, Ontario, L8G 1H1
North York Research Inc /ID# 213486
Toronto, Ontario, M2N 3A6
University of British Columbia - Eye Care Centre, Vancouver General Hospital /ID# 213507
Vancouver, British Columbia, V5Z 3N9
Private Practice - Dr. Kim Papp Clinical Research /ID# 212130
Waterloo, Ontario, N2J 1C4
Dr Maksym Breslavets Medicine Professional Corporation /ID# 213338
Whitby, Ontario, L1N 8M7
Winnipeg Clinic /ID# 212134
Winnipeg, Manitoba, R3C 0N2
France27 sites
CH du Pays d'AIX /ID# 216440
Aix-en-Provence, 13616
CHU Amiens-Picardie Site Sud /ID# 216170
Amiens, Somme, 80054
Chu Angers /Id# 216244
Angers, 49933
Ch Auxerre /Id# 216175
Auxerre, Yonne, 89011
Hopital Ambroise Pare /ID# 216439
Boulogne-Billancourt, 92104
Hopital de la Cavale Blanche /ID# 216495
Brest, Finistere, 29200
CHU de CAEN - Hopital de la Cote de Nacre /ID# 216245
Caen, Calvados, 14033
Cabinet Dermatologie et Esthetique /ID# 229132
Cannes, 06400
CH William Morey /ID# 225441
Chalon-sur-Saône, 71321
Ch Chalons En Champagne /Id# 216668
Châlons-en-Champagne, Marne, 51000
Centre Hospitalier Métropole Savoie - Site Hôpital de Chambéry /ID# 217572
Chambéry, Savoie, 73007
CHU Dijon /ID# 216247
Dijon, Cote-d Or, 21000
CH Annecy Genevois - Site Annecy /ID# 225786
Epagny Metz Tessy, 74370
CHU Grenoble - Hopital Michallon /ID# 218437
La Tronche, Isere, 38700
Centre Hospitalier du Mans /ID# 225729
Le Mans, Sarthe, 72037
C.H. de Bretagne Sud /ID# 216243
Lorient, 56322
Hopital Saint Joseph /ID# 223149
Marseille, Bouches-du-Rhone, 13008
CH Georges Renon /ID# 216174
Niort, Deux-Sevres, 79028
CH Pontoise - Hopital René Dubos /ID# 216169
Pontoise, Val-d Oise, 95300
CHU de Rennes - PONTCHAILLOU /ID# 218248
Rennes, Brittany Region, 35000
Hopitaux Drome Nord /ID# 222586
Romans-sur-Isère, Drome, 26100
Hôpital d'instruction des armées Bégin /ID# 216167
Saint-Mandé, 94163
Centre Hospitalier Universitaire de Saint Etienne - Hopital Nord /ID# 216663
St-Priest-en-Jarez, Pays de la Loire Region, 42270
CH Bigorre - Site de la Gespe /ID# 218563
Tarbes, Hautes-Pyrenees, 65013
CHR Metz-Thionville - Hopital Bel-Air /ID# 225691
Thionville, Moselle, 57100
Hôpital d'Instruction des Armées Sainte-Anne /ID# 218888
Toulon, Var, 83800
CH Valence /ID# 225877
Valence, Drome, 26000
Japan27 sites
Asahikawa Medical University Hospital /ID# 213409
Asahikawa-shi, Hokkaido, 078-8510
Nippon Medical School Hospital /ID# 213391
Bunkyo-ku, Tokyo, 113-8603
St. Lukes International Hospital /ID# 213392
Chuo-ku, Tokyo, 104-8560
Fukuoka University Hospital /ID# 213395
Fukuoka, Fukuoka, 814-0180
University of the Ryukyus Hospital /ID# 213394
Ginowan-shi, Okinawa, 901-2725
Kansai Medical University Hospital /ID# 213388
Hirakata-shi, Osaka, 573-1191
Imamura General Hospital /ID# 228450
Kagoshima, Kagoshima-ken, 890-0064
Kurume University Hospital /ID# 215034
Kurume-shi, Fukuoka, 830-0011
University Hospital Kyoto Prefectural University of Medicine /ID# 213396
Kyoto, Kyoto, 602-8566
Kyoto University Hospital /ID# 213404
Kyoto, Kyoto, 606-8507
Shinshu University Hospital /ID# 213408
Matsumoto-shi, Nagano, 390-8621
Matsuyama Red Cross Hospital /ID# 224745
Matsuyama, Ehime, 790-8524
Chukyo Hospital /ID# 213405
Nagoya, Aichi-ken, 457-8510
Nagoya City University Hospital /ID# 213363
Nagoya, Aichi-ken, 467-8602
Takagi Dermatological Clinic /ID# 213407
Obihiro-Shi, Hokkaido, 080-0013
Nippon Life Saiseikai Public Interest Foundation Nippon Life Hospital /ID# 224743
Osaka, 550-0006
JR Sapporo Hospital /ID# 213406
Sapporo, Hokkaido, 060-0033
Jichi Medical University Hospital /ID# 213403
Shimotsuke-shi, Tochigi, 329-0498
Tokyo Medical University Hospital /ID# 217125
Shinjuku-ku, Tokyo, 160-0023
Japan Community Health care Organization Tokyo Yamate Medical Center /ID# 213389
Shinjuku-ku, Tokyo, 169-0073
Shizuoka General Hospital /ID# 224744
Shizuoka, Shizuoka, 420-8527
Takamatsu Red Cross Hospital /ID# 222875
Takamatsu, Kagawa-ken, 760-0017
Takamatsu Red Cross Hospital /ID# 241120
Takamatsu, Kagawa-ken, 760-0017
The Jikei University School of Medicine /ID# 213393
Tokyo, 105-8461
Teikyo University Hospital /ID# 213362
Tokyo, 173-8605
Duplicate_Fujita Health University Hospital /ID# 224742
Toyoake-shi, Aichi-ken, 470-1192
Mie University Hospital /ID# 213387
Tsu, Mie-ken, 514-8507
Spain27 sites
Hospital Universitario Principe de Asturias /ID# 225085
Alcalá de Henares, Madrid, 28805
Hospital Universitario del Sureste /ID# 226561
Arganda, Madrid, 28500
Hospital Universitario de Bajadoz /ID# 225091
Badajoz, 06080
Hospital Santa María del Rosell /ID# 225100
Cartagena, Murcia, 30203
Hospital Universitario de Getafe /ID# 225086
Getafe, Madrid, 28905
Hospital Universitario Virgen de las Nieves /ID# 225107
Granada, 18014
Hospital Juan Ramon Jimenez /ID# 225105
Huelva, 21005
Hospital Universitario Severo Ochoa /ID# 225087
Leganés, Madrid, 28911
Hospital de Leon /ID# 226559
León, 24071
Hospital Universitario Lucus Augusti /ID# 233282
Lugo, 27003
Hospital General Universitario Gregorio Maranon /ID# 231664
Madrid, 28007
Hospital Universitario Ramon y Cajal /ID# 225093
Madrid, 28034
Hospital Universitario 12 de Octubre /ID# 238474
Madrid, 28041
Hospital Universitario Puerta de Hierro - Majadahonda /ID# 225084
Majadahonda, Madrid, 28222
Hospital de Manacor /ID# 225083
Manacor, Balearic Islands, 07500
Hospital General de Mostoles /ID# 225088
Móstoles, Madrid, 28935
Hospital San Telmo /ID# 233283
Palencia, 34004
Hospital Universitari Son Espases /ID# 233286
Palma de Mallorca, Balearic Islands, 07120
Hospital Universitario de Puerto Real /ID# 225103
Puerto Real, Cadiz, 11510
Hospital Universitario de Salamanca /ID# 225078
Salamanca, 37711
Complejo Hospitalario Universitario de Santiago (CHUS) /ID# 225076
Santiago de Compostela, A Coruna, 15706
Hospital Universitario Virgen de Valme /ID# 225104
Seville, 41014
Hospital Alvaro Cunqueiro CHUVI /ID# 225077
Vigo, Pontevedra, 36213
Hospital Virgen de la Concha /ID# 233285
Zamora, 49022
Hospital Clinico Universitario Lozano Blesa /ID# 231663
Zaragoza, 50009
Hospital Universitario Miguel Servet /ID# 225080
Zaragoza, 50009
Hospital Royo Villanova /ID# 231665
Zaragoza, 50015
Italy20 sites
Azienda Ospedaliero Universitaria delle Marche /ID# 218720
Ancona, 60020
A.O.U. Consorziale Policlinico di Bari /ID# 218558
Bari, 70124
ASST degli Spedali Civili di Brescia /ID# 218717
Brescia, 25123
AOU Policlinico G. Rodolico - San Marco /ID# 219032
Catania, 95123
Università degli Studi di Firenze /ID# 221383
Florence, Firenze, 50122
Ospedale San Martino /ID# 218844
Genoa, Genova, 16132
Azienda Ospedaliera Universitaria Mater Domini- Campus Salvatore Venuta /ID# 218902
Germaneto, Catanzaro, 88100
ASL 1 Abruzzo - Ospedale regionale San Salvatore /ID# 218719
L’Aquila, L Aquila, 67100
IRCCS Policlinico San Donato /ID# 222002
Milan, 20097
IRCCS Istituto Ortopedico Galeazzi /ID# 218867
Milan, 20161
Azienda Ospedaliera Universitaria Federico II /ID# 218808
Naples, Napoli, 80131
Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 218546
Naples, Napoli, 80138
Azienda Ospedale-Universita Padova /ID# 221299
Padova, 35128
Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia /ID# 219033
Perugia, 06156
Azienda Ospedaliero Universitaria Pisana /ID# 218555
Pisa, 56126
Azienda Ospedaliera Universitaria Policlinico Tor Vergata /ID# 219031
Rome, Roma, 00133
Presidio Columbus-Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Un /ID# 218718
Rome, Roma, 00168
IRCCS Istituto Clinico Humanitas /ID# 218560
Rozzano, Lombardy, 20089
Sapienza University of Rome - Polo Pontino /ID# 218557
Terracina, Latina, 04019
Azienda ULSS 8 Berica /ID# 218845
Vicenza, 36100
United Kingdom16 sites
Ulster Hospital - South Eastern Health & Social Care Trust /ID# 215477
Belfast, BT16 1RH
Cwm Taf Morgannwg University Health Board /ID# 215974
Bridgend, Wales, CF31 1RQ
West Suffolk Hospital /ID# 249283
Bury St Edmunds, Suffolk, IP33 2QZ
Frimley Health NHS Foundation Trust /ID# 215976
Camberley, Surrey, GU16 7UJ
Addenbrookes Hospital /ID# 215972
Cambridge, Cambridgeshire, CB2 2QQ
The Dudley Group NHS Foundation Trust /ID# 215839
Dudley, DY1 2HQ
Western General Hospital - NHS Lothian /ID# 249287
Edinburgh, Edinburgh, City of, EH4 2XU
The Queen Elizabeth Hospital, Kings Lynn NHS Foundation Trust /ID# 215476
Kings Lynn, Norfolk, PE30 4ET
Kingston Hospital NHS Foundation Trust /ID# 215973
Kingston upon Thames, Surrey, KT2 7QB
Kingston Hospital NHS Foundation Trust /ID# 230856
Kingston upon Thames, Surrey, KT2 7QB
Hammersmith Hospital /ID# 215978
London, England, W12 0HS
Sandwell and West Birmingham Hospitals NHS Trust /ID# 249294
Lyndon, B71 4HJ
Northern Care Alliance NHS Group /ID# 218589
Manchester, M8 5RB
The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 215479
Newcastle upon Tyne, NE3 3HD
Northampton General Hospital NHS Trust /ID# 249297
Northampton, Northamptonshire, NN1 5BD
York Hospital /ID# 227940
York, North Yorkshire, YO31 8HE
Argentina11 sites
Professional Skin Care /ID# 218514
Buenos Aires, 1024
Hospital Italiano /ID# 217000
CABA, C1199ABB
Stringa Dermatologia /ID# 218450
Ciudad Autonoma Buenos Aires, Buenos Aires F.D., 1114
Private Office Cristina Echeverria /ID# 222082
Ciudad Autonoma Buenos Aires, Buenos Aires F.D., 1425
Stat Research /ID# 217185
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., 1023
Buenos Aires Skin /ID# 217657
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., 1055
CEDIC Centro de Investigaciones Clinicas /ID# 217184
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., 1425
Instituto de Neumonologia y Dermatologia /ID# 217429
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., 1425
Psoriahue Med Interdisciplinar /ID# 217182
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., 1425
Emiliano Baccarini Priv Practice /ID# 218581
Lomas de Zamora, Buenos Aires, 1832
Hospital Universitario Austral /ID# 217540
Pilar, Buenos Aires, 1629
Austria9 sites
Hautarzt Dr. Lukas Kraus /ID# 216139
Dornbirn, Vorarlberg, 6850
Medizinische Universitaet Graz /ID# 217702
Graz, Styria, 8010
Haut Trattner Dermatologie /ID# 216138
Hainfeld, 3170
Klinik Landstrasse /ID# 217684
Vienna, State of Vienna, 1030
Medizin am Hauptbahnhof /ID# 218837
Vienna, State of Vienna, 1100
EZW HAUT Entzuendungszentrum Wien /ID# 215488
Vienna, State of Vienna, 1130
Klinik Hietzing /ID# 217685
Vienna, State of Vienna, 1130
Klinik Donaustadt /ID# 218842
Vienna, State of Vienna, 1220
Klinikum Wels-Grieskirchen GmbH /ID# 216140
Wels, Upper Austria, 4600
Colombia9 sites
Ciensalud IPS S.A.S /ID# 244608
Barranqulla, 080016
Sociedad de Cirugía de Bogotá- Hospital de San José /ID# 222683
Bogota, Cundinamarca, 111711
Caja de Compensación Familiar Cafam, Sede Centro de Atención En Salud Cafam Flor /ID# 222660
Bogotá, Cundinamarca, 110221
Centro Dermatológico Federico Lleras Acosta E.S.E /ID# 222686
Bogotá, Cundinamarca, 111511
Fundacion hospitalaria San Vicente de Paul /ID# 222680
Medellín, Antioquia, 050010
Centro de Inmunología y Genética CIGE SAS /ID# 222685
Medellín, Antioquia, 055422
IPS Universitaria /ID# 241832
Medellín, Antioquia, 50010
Fundacion Hospital Universidad del Norte /ID# 223428
Soledad, Atlántico, 83001
Healthy Medical Center S.A.S /ID# 231909
Zipaquirá, Cundinamarca, 250252
Mexico8 sites
Centro Dermatologico Del Country S de Rl de Cv /Id# 225460
Guadalajara, Jalisco, 44610
Grupo Clinico Catei Sociedad Civil /Id# 216978
Guadalajara, Jalisco, 44657
RM Pharma Specialists S.A de C.V. /ID# 225458
Mexico City, Mexico City, 03100
Consultorio Privado /Id# 225457
Mexico City, Mexico City, 06500
Clinica Los Arcos Iztapalapa /Id# 216982
Mexico City, Mexico City, 09260
Centro Especializado en Diabetes, Obesidad y Prevención Cardiovascular (Cedopec) /ID# 216979
Mexico City, Mexico City, 11650
Dermatologica Sc /Id# 225449
Tijuana, Estado de Baja California, 22010
Neki Servicios Medicos Profesionales S D Rl de Cv /Id# 216977
Toluca, 50120
Australia6 sites
Skin Health Institute Inc /ID# 217619
Carlton, Victoria, 3053
Northern Dermatology /ID# 218374
Chermside, Queensland, 4032
Fremantle Dermatology /ID# 217617
Fremantle, Western Australia, 6160
Premier Specialist /ID# 218158
Kogarah, New South Wales, 2217
Kingsway Dermatology & Aesthetics /ID# 217616
Miranda, New South Wales, 2228
Veracity Clinical Research /ID# 217618
Woolloongabba, Queensland, 4102
Czechia6 sites
Nemocnice Ceske Budejovice a.s. /ID# 216310
České Budějovice, 370 01
Fakultní nemocnice Hradec Králové - Sokolská /ID# 222670
Hradec Králové, Hradec Kralove, 500 05
Fakultni nemocnice Olomouc /ID# 215901
Olomouc, 779 00
Fakultni nemocnice Kralovske Vinohrady /ID# 233184
Prague, 100 34
Sanatorium profesora Arenbergera /ID# 215489
Prague, 110 00
Duplicate_Fakultni Nemocnice v Motole /ID# 215484
Prague, 150 00
Switzerland5 sites
University Hospital Basel /ID# 212744
Basel Town, Canton of Basel-City, 4031
Inselspital, Universitaetsspital Bern /ID# 212741
Bern, 3010
Waldhotel Health & Medical Excellence /Id# 212743
Obbürgen, Canton of Nidwalden, 6363
Haut. Venen. Allergie. Zentrum Brunnehof /ID# 212742
Uster, Canton of Zurich, 8610
University Hospital Zurich /ID# 216539
Zurich, Canton of Zurich, 8091
United Arab Emirates5 sites
Mediclinic Khalifa Branch /ID# 217871
Abu Dhabi
New Medical Center Hospital /ID# 223681
Abu Dhabi
Skmc /Id# 217873
Abu Dhabi
Tawam Hospital /ID# 217872
Abu Dhabi
Mediclinic Welcare Hospital /ID# 223683
Dubai
Hungary4 sites
Debreceni Egyetem-Klinikai Kozpont /ID# 212959
Debrecen, Hajdú-Bihar, 4032
Pecsi Tudomanyegyetem Klinikai Kozpont /ID# 212960
Pécs, Baranya, 7624
Szegedi Tudomanyegyetem /ID# 212958
Szeged, 6720
Vas Varmegyei Markusovszky Egyetemi Oktatokorhaz /ID# 212961
Szombathely, Vas County, 9700
Netherlands4 sites
Medisch Centrum Leeuwarden /ID# 215779
Leeuwarden, Provincie Friesland, 8934 AD
Radboud Universitair Medisch Centrum /ID# 213592
Nijmegen, Gelderland, 6525 GA
Laurentius Ziekenhuis /ID# 230503
Roermond, Limburg, 6043 CV
Haaglanden Medisch Centrum /ID# 232063
The Hague, 2512 VA
Poland4 sites
COPERNICUS Podmiot Leczniczy Sp. z o.o. - Szpital sw. Wojciecha Adalberta /ID# 225446
Gdansk, Pomeranian Voivodeship, 80-462
Labderm S.C. Beata Bergler-Czop, Barbara Sido-Bergler /Id# 225447
Ożarowice, Silesian Voivodeship, 42-624
KSW nr1 w Rzeszowie /ID# 225444
Rzeszów, Podkarpackie Voivodeship, 35-055
Panstwowy Instytut Medyczny MSWiA w Warszawie /ID# 225415
Warsaw, Masovian Voivodeship, 02-507
Romania4 sites
Spitalul Clinic Colentina /ID# 214307
Bucharest, 020121
Spitalul Clinic Colentina /ID# 224810
Bucharest, 020121
Spitalul Clinic Colentina /ID# 224811
Bucharest, 020121
Spitalul Clinic Județean de Urgențe "Sfântul Spiridon" /ID# 214335
Iași, 700111
Saudi Arabia4 sites
Heraa General Hospital /ID# 217214
Mecca
King Abdulaziz Medical City- National Guard Hospital /ID# 224354
Riyadh, Riyadh Region, 11426
King Saud University Med City /ID# 219065
Riyadh, 12372
Security Forces Hospital /ID# 221073
Riyadh, 12625
Ireland3 sites
South Infirmary Victoria University Hospital /ID# 213001
Cork, T12 X23H
University Hospital Limerick /ID# 216997
Limerick, V94 F858
Tallaght University Hospital /ID# 212999
Tallaght, Dublin, Dublin, D24 NR0A
About this study
Official title: Multi-Country Prospective ObserVAtionaL, Cohort Study of Patients With Moderate to Severe Chronic PlaqUE Psoriasis (VALUE)
This study will assess the use of risankizumab in adult patients with moderate to severe chronic plaque psoriasis and compare risankizumab to other commonly used biologics.
- Conditions
- Chronic Plaque Psoriasis
- Keywords
- Chronic Plaque Psoriasis Risankizumab Biologics Psoriasis Vulgaris
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Participants treated with other approved biological therapies | Treatment decision independently made of study enrollment | |
| Participants treated with Risankizumab | Treatment decision independently made of study enrollment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of participants who achieved Psoriasis Area and Severity Index (PASI) 90
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination.
Measured: From Month 4 to 3 years
Time to first treatment change
Identify time to first treatment change including discontinuation, dose escalation and dosing interval shortening
Measured: From Week 0 (Baseline) to first treatment change
Secondary outcomes (13)
Time to first treatment change rate
Time to first treatment change including discontinuation, dose escalation and dose interval shortening.
Measured: At 1 year, 2 year, and 3 year
Percentage of participants who achieved Static Physicians Global Assessment (sPGA) 0/1 or sPGA 0
The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. sPGA scores demonstrate overall psoriatic disease with a lower score indicating less body coverage. The assessment is considered "static" which refers to the patients disease state at the time of the assessments, without comparison to any of the patient's previous disease states, whether at Baseline or at a previous visit.
Measured: Monthly for up to 3 years
Percentage of participants who achieved Psoriasis Area and Severity Index (PASI) 75, 90, or 100
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. Each threshold will be analyzed separately.
Measured: Monthly for up to 3 years
Percentage of participants who achieved Absolute PASI<=5, <=3 or <=1
Used to assess the benefit of psoriasis therapy. Each threshold will be analyzed separately.
Measured: Monthly for up to 3 years
Time to achieve sPGA 0/1 or sPGA 0
The sPGA is the assessment by the Investigator of the overall disease severity at the time of evaluation. The National Psoriasis Foundation Psoriasis Score version of a static PGA is calculated by averaging the total body erythema, induration, and desquamation scores.
Measured: Up to 3 years
Time to achieve PASI 75, 90,or 100
PASI 75, 90, or 100 defined as at least a 75%/ 90%/ 100% reduction in PASI relative to Week 0 (Baseline). Each threshold will be analyzed separately.
Measured: Up to 3 years
Percentage of participants who achieve sPGA 0/1 or sPGA 0 at 4 Months and maintained the response status at 1 Year, 2 Years and 3 Years without increasing the dose or shortening the dose interval
Percentage of participants who achieve sPGA 0/1 or sPGA 0 at 4 Months and maintained the response status at 1 Year, 2 Years and 3 Years without increasing the dose or shortening the dose interval.
Measured: At 4 months to 1 year, 2 years, and 3 years
Percentage of participants who achieved PASI 90 or PASI 100 at 4 Months and maintained the response status at 1 Year, 2 Years, and 3 Years without changing the indicated dose or dosing interval
Percentage of participants who achieved PASI 90 or PASI 100 demonstrating a 90 or 100% reduction in PASI at 4 Months and maintained the response status at 1 Year, 2 Years, and 3 Years without changing the indicated dose or dosing interval.
Measured: At 4 months and 1 year, 2 years, and 3 years
Change in PASI
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination.
Measured: From Week 0 to up to 3 years
Change in Body Surface Area (BSA)
BSA can be used to quantify the severity of psoriasis. A decrease in BSA affected by psoriasis indicates improvement.
Measured: From Week 0 to up to 3 years
Change in Dermatology Quality of Life Index (DLQI) Score
The Dermatology Life Quality Index (DLQI) is the most commonly used quality of life (QoL) assessment tool. The DLQI is a self-administered, ten-question questionnaire used to assess the effect of different skin diseases on a subject's quality of life, overall health, and disability status. Scores range from 0 (not relevant/not at all) to 3 (very much).
Measured: From Week 0 to up to 3 years
Percentage of participants who achieve DLQI 0/1
The Dermatology Life Quality Index (DLQI) is the most commonly used quality of life (QoL) assessment tool. The DLQI is a self-administered, ten-question questionnaire used to assess the effect of different skin diseases on a subject's quality of life, overall health, and disability status. The higher the DLQI score, the more quality of life is impaired.
Measured: Monthly for up to 3 years
Change in Treatment Satisfaction Questionnaire for Medication (TSQM) score
The Treatment Satisfaction Questionnaire for Medication (TSQM) is a widely used generic measure to assess treatment satisfaction with their medication. This is a 100-point scale with higher scores indicating greater satisfaction with medication and provides scores on four scales - side effects, effectiveness, convenience and global satisfaction.
Measured: From Week 0 to up to 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jun 2019
- Study start1 Jul 2019
- Primary completion2 Sep 2025
- Study completion2 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Chronic Plaque PsoriasisStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,759 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03982394
- Sponsor's protocol ID
- P19-377
- Acronym
- VALUE
- Status last verified
- Nov 2025
- First submitted
- 10 Jun 2019
- Last updated
- 17 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Thaci D, Ohtsuki M, Maul JT, Szegedi A, Luna PC, Lynde CW, Soliman AM, Wang H, Kaufmann C, Ashley DG, Madihlaba T, Rubant S, Papp KA. Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months. Dermatol Ther (Heidelb). 2025 Feb;15(2):381-394. doi: 10.1007/s13555-025-01342-0. Epub 2025 Feb 4.
PubMed 39904971
Study at a glance
From the registry record, last updated by the sponsor on 17 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multi-Country Prospective ObserVAtionaL, Cohort Study of Patients With Moderate to Severe Chronic PlaqUE Psoriasis (VALUE)
- ClinicalTrials.gov ID
- NCT03982394
- Acronym / sponsor ID
- VALUE / P19-377
- Conditions
- Chronic Plaque Psoriasis
- Keywords
- Chronic Plaque Psoriasis Risankizumab Biologics Psoriasis Vulgaris
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 2,759 participants (actual)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 1 Jul 2019 (actual)
- Primary completion
- 2 Sep 2025 (actual)
- Study completion
- 2 Sep 2025 (actual)
- First posted
- 11 Jun 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will assess the use of risankizumab in adult patients with moderate to severe chronic plaque psoriasis and compare risankizumab to other commonly used biologics.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Participants treated with other approved biological therapies | – | –Treatment decision independently made of study enrollment |
| Participants treated with Risankizumab | – | –Treatment decision independently made of study enrollment |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This study will enroll adult subjects with moderate to severe plaque psoriasis.
Key inclusion criteria (3 listed)
- Confirmed diagnosis of moderate to severe chronic plaque-type psoriasis diagnosed by a specialist and presence of moderate to severe psoriasis symptoms according to physician's judgement at time of recruitment.
- Participant starting any approved treatment for psoriasis and physician's decision must be reached prior to recruitment in the study.
- Participant willing to continue with study documentation after cessation of therapy.
Key exclusion criteria (2 listed)
- Unwillingness or inability to comply with study requirements.
- Participation in an interventional clinical trial, concurrently or within the last 30 days. Participation in a post-market observational study (PMOS) or Registry is acceptable.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Percentage of participants who achieved Psoriasis Area and Severity Index (PASI) 90
Time frame: From Month 4 to 3 years
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination.
Time to first treatment change
Time frame: From Week 0 (Baseline) to first treatment change
Identify time to first treatment change including discontinuation, dose escalation and dosing interval shortening
13 secondary outcomes
Time to first treatment change rate
Time frame: At 1 year, 2 year, and 3 year
Percentage of participants who achieved Static Physicians Global Assessment (sPGA) 0/1 or sPGA 0
Time frame: Monthly for up to 3 years
Percentage of participants who achieved Psoriasis Area and Severity Index (PASI) 75, 90, or 100
Time frame: Monthly for up to 3 years
Percentage of participants who achieved Absolute PASI<=5, <=3 or <=1
Time frame: Monthly for up to 3 years
Time to achieve sPGA 0/1 or sPGA 0
Time frame: Up to 3 years
Time to achieve PASI 75, 90,or 100
Time frame: Up to 3 years
Percentage of participants who achieve sPGA 0/1 or sPGA 0 at 4 Months and maintained the response status at 1 Year, 2 Years and 3 Years without increasing the dose or shortening the dose interval
Time frame: At 4 months to 1 year, 2 years, and 3 years
Percentage of participants who achieved PASI 90 or PASI 100 at 4 Months and maintained the response status at 1 Year, 2 Years, and 3 Years without changing the indicated dose or dosing interval
Time frame: At 4 months and 1 year, 2 years, and 3 years
Change in PASI
Time frame: From Week 0 to up to 3 years
Change in Body Surface Area (BSA)
Time frame: From Week 0 to up to 3 years
Change in Dermatology Quality of Life Index (DLQI) Score
Time frame: From Week 0 to up to 3 years
Percentage of participants who achieve DLQI 0/1
Time frame: Monthly for up to 3 years
Change in Treatment Satisfaction Questionnaire for Medication (TSQM) score
Time frame: From Week 0 to up to 3 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Nov 2025.
- Derived from this study: PubMed 39904971Thaci D, Ohtsuki M, Maul JT, Szegedi A, Luna PC, Lynde CW, Soliman AM, Wang H, Kaufmann C, Ashley DG, Madihlaba T, Rubant S, Papp KA. Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months. Dermatol Ther (Heidelb). 2025 Feb;15(2):381-394. doi: 10.1007/s13555-025-01342-0. Epub 2025 Feb 4.
- Related infoLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for Chronic Plaque Psoriasis
Active, not recruitingPhase 3
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
Psoriasis
RecruitingObservational study
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
Acne, Atopic Dermatitis
RecruitingPhase 4
An Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail Psoriasis
Chronic Plaque Psoriasis, Nail Psoriasis
RecruitingPhase 2
Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?
Psoriasis
RecruitingObservational study
Serum Substance P, Neuropathic Pain, and Central Sensitization Across Treatment Groups in Chronic Plaque Psoriasis
Chronic Plaque-type Psoriasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
ABBVIE INC. study director
AbbVie
302 sites in 21 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Plaque Psoriasis, run by AbbVie at 302 sites in 21 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 302 sites in Germany, Canada, France, Japan, Spain and 16 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of participants who achieved Psoriasis Area and Severity Index (PASI) 90 (time frame: From Month 4 to 3 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03982394, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Nov 2025.